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Background: Recently, a growing body of evidence on the possible role of residual platelet reactivity (RPR) in affecting clinical events has
accumulated. The aim of this study was to systematically assess the relationship between RPR on acetylic salicylic acid (ASA) therapy and
the occurrence of recurrent events in a meta-analysis of prospective studies.
Methods: A systematic literature search of MEDLINE, EMBASE, Science Citation Index, the Cochrane Systematic Review Database and
bibliographies of retrieved articles through May 2007 was conducted. Studies were included if they analysed RPR in coronary heart disease
patients in relation to the occurrence of adverse coronary events during follow-up.
Results: Eleven prospective studies, incorporating 1952 patients with coronary heart disease followed for a time ranging from 6 days to
4 years, met the inclusion criteria. The pooled analysis demonstrated a significantly increased relative risk of adverse clinical events during
follow-up for patients with RPR on ASA therapy (RR: 3.11, 95%CI 1.88–5.15; pb0.0001). Moreover, the association between RPR and
cardiovascular recurrences remained to be statistically significant even when subgroup analyses performed according to the duration of
follow-up, ASA dosage, characteristics of the study population, and laboratory method were conducted.
Conclusions: The present meta-analysis documents a significant association between RPR on ASA treatment and recurrent cardiovascular
events. More prospective studies are needed to determine the independent prognostic importance of RPR during aspirin therapy and possible
benefit of individually tailored anti-platelet treatment strategies in these patients.
© 2007 Elsevier Ireland Ltd. All rights reserved.Keywords: Aspirin; Antiplatelet therapy; Residual platelet reactivity; Recurrence; Meta-analysis1. Introduction
Antiplatelet drugs have an established place in the sec-
ondary prevention of a variety of vascular events, such as fatal
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doi:10.1016/j.ijcard.2007.12.010ripheral arterial disease [1]. Indeed, results from the meta-
analysis of the “Antiplatelet Trialists’ Collaboration” demon-
strated that acetyl salicylic acid (ASA) therapy is able to reduce
the risk of non-fatal myocardial infarction by 35% and the risk
of total vascular events by 18% in patients with manifest
coronary heart and cerebrovascular disease [1].
However, in a consistent proportion of vascular patients on
ASA therapy residual platelet reactivity (RPR), the so-called
aspirin resistance, is detectable [2]. A systematic review that
recently assessed the prevalence of RPR in patients with CHD
on ASA therapy reported an overall prevalence of 25% among
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nomenon has a significant clinical implication on the oc-
currence of atherothrombotic events has not been, to date,
definitely answered. Some studies evaluating the occurrence of
clinical events during follow-up in patients with RPRhave been
conducted [4–6], and a recent meta-analysis by Snoep et al.,
evidenced an association between a laboratory-defined aspirin
resistance and a higher risk of recurrent cardiovascular events
[7]. The aim of this study is to systematically review all the
available studies that prospectively investigated the possible
association between RPR on ASA therapy and the occurrence
of major adverse cardiovascular events in patients with CHD.
2. Methods
2.1. Search strategy
An extensive systematic literature search in order to
identify studies evaluating the association between RPR and
the occurrence of secondary cardiovascular events was con-
ducted. The search was performed by using a combined text
word and MeSH search strategy of the terms “acetyl salicylic
acid”, “aspirin”, “antiplatelet”, “residual platelet reactivity”,
and “persistent platelet reactivity” in combination with
“resistance”, “failure”, “recurrence” and “major adverse
cardiovascular events”, “cardiovascular disease”, “coronary
artery disease”, “coronary heart disease”, “ischemic heart
disease”, “myocardial infarction”, and “acute coronary
syndromes” through the electronic databases MEDLINE
(from 1966 to May 2007), EMBASE (from 1974 to May
2007), Science Citation Index (from 1994 to May 2007), and
the Cochrane Systematic Review databases. Furthermore, a
manual search of citations from relevant original studies and
review articles was performed.
2.2. Study eligibility
To be included in the analysis, studies had to fulfil the
following criteria:
• Prospective study design
• CHD patients
• Patients on ASA therapy for secondary prevention of
cardiovascular events
• Clear definition of RPR
• Clear definition of laboratory methods used to identify
RPR
• Relative risk, hazard ratio, or odds ratio and their corre-
sponding 95% confidence intervals (or data to calculate
them)
2.3. Study selection and data collection
All data were independently extracted by 2 investigators
(F.S., and R.M.) through the use of a standardized data
extraction tool and entered into separate databases. Resultswere compared, and disagreements were resolved by dis-
cussion with a third investigator (A.M.G.). The interobserver
agreement for the study selection was 0.90. Relevant data
included the first author's name, year of publication, country
of origin of the centres, number of participants and number of
patients with RPR, ASA dosage, duration of follow-up, par-
ticipants' age, gender of participants, number of patients with
clinical recurrences at follow-up, laboratory method used to
measure RPR, definition of RPR, relative risks or hazard
ratios of CHD and corresponding 95% CI, and covariates
adjusted in the statistical analysis.
2.4. Statistical analyses
Data were analyzed by using Review Manager (RevMan)
software for Windows (version 4.2) by the Cochrane
Collaboration, 2003 and Statistical Package for Social Sciences
(SPSS) software for Windows (version 13.0). The ĸ statistic
was used to assess agreement between reviewers for study
selection. The results of each study were reported as relative
risk (RR), hazard ratio, or dichotomous frequency data. Hazard
ratios were treated as RRs, whereas frequency data were
algebraically converted into RRs.When available, we used the
results of the original studies from multivariable models with
the most complete adjustment for potential confounders; the
confounding variables included in this analysis are shown in
Table 1. We used a random-effects model which accounts for
interstudy variation and provides a more conservative effect
than the fixed model. Thus, we calculated random-summary
RR with 95% confidence intervals (CI), by using inverse-
variance method. The potential sources of heterogeneity were
assessed by using the Cochran'sQ test to assess between-study
differences and the I2 statistic to quantify the proportion of
inconsistency across the study results. Publication bias was
assessed using a funnel plot of effect size against standard error.
3. Results
3.1. Search results
The search strategy generated 26 potentially relevant
studies. Eight studies were eliminated because they were not
prospective studies, 4 because they reported only clopidogrel
resistance, 2 because they did not evaluate clinical cardio-
vascular recurrences during the follow-up but only surrogate
markers, and 1 because only a meeting abstract was avail-
able. As a result, a total of 11 prospective studies were
included in the meta-analysis [8–18].
3.2. Studies' characteristics
Characteristics of the included studies are presented in
Table 1.
The included studies comprehended a total of 1952
patients with CHD followed for a time ranging from 6 days
to 4 years, with study sample sizes ranging from 71 to 326
Table 1
Characteristics of the studies included in the meta-analysis
Study author, year
(country)
Patients
with
residual
platelet
activity/
patients
Type of
patients
Aspirin
dosage
Follow-up Age Males/
females
Clinical
recurrences,
n
Laboratory
method
Definition of
residual
platelet
reactivity
Adjustment
factors
Gum et al.,
2003
[8] (U.S.A.)
17/326 Stable
CHD
325
mg/die
679 days 60 253/73 34 Platelet
aggregation
(10 µM ADP
and 0.5 mg/
mL AA)
Aggregation
≥70% with
10 µM ADP
and ≥20%
with 0.5 mg/
mL AA
Age, gender, race, smoking
habit, diabetes, hypertension,
dyslipidemia,
revascularization,
myocardial infarction,
haemoglobin, platelet count,
creatinine, aspirin sensitivity
Andersen
et al., 2003
[9] (Norway)
25/71 AMI 160
mg/die
4 years 71 56/15 20 PFA-100 Closure time
EPI ≤196 s
None
Marcucci et al.,
2006 [10]
(Italy)
41/146 AMI 100
mg/die
1 year 65 115/31 44 PFA-100 Closure time
EPI b203 s
Age, gender, diabetes, no.
of stenosed coronary
arteries, left ventricular
ejection
fraction
Gianetti et al.,
2006 [11]
(Italy)
76/175 ACS
and
stable
angina
Not
reported
6 months Not
reported
108/67 6 PFA-100 Closure time
EPI b190 s
Age, diabetes, smoking
habit, hypertension, LDL-
cholesterol
Fuchs et al.,
2006 [12]
(Austria)
Not
reported/
208
ACS Not
reported
28 months ~60 175/33 58 PFA-100 Closure time
EPI b300 s
Diabetes, von Willebrand
factor, beta-blockers,
clopidogrel
Stejskal et al.,
2006 [13]
(Czech
Republic)
46/103 ACS 100
mg/die
4 years 64 66/37 79 Spontaneous
and after
induction of
cationic
propyl
gallate-
platelet
aggregation
Spontaneous
aggregation
N5%
None
Slope of the
aggregation
curve after
induction
N53%/min
Pamukcu et al.,
2006 [14]
(Turkey)
20/195 ACS 100–300
mg/die
1 year 18–80 172/23 19 PFA-100 Closure time
b186 s
Not reported
Cuisset et al., 2006
[15] (France)
26/106 ACS 160
mg/die
1 month 64.2 82/24 12 Platelet
aggregation
(0.5 mg/
mL AA)
Upper
quartile of
AA-induced
platelet
aggregation
Age, gender, traditional
cardiovascular risk factors,
treatment, c-reactive protein,
P-selectin
Malek et al., 2007
[16] (Poland)
9/91 ACS 75
mg/die
6 days ~60 62/29 11 PFA-100 Closure time
EPI b190 s
None
Pamukcu et al.,
2007 [17]
(Turkey)
52/234 Stable
CHD
100–300
mg/die
20.6
months
57 182/52 28 PFA-100 Closure time
EPI b186 s
None
Poulsen et al. 2007
[18] (Denmark)
70/297 AMI 150
mg/die
1 year ~70 239/59 49 PFA-100 Closure time
EPI b165 s
None
Data are for patients included in analyses of recurrent cardiovascular events, and may differ from the characteristics of the total study populations.
CHD = Coronary Heart Disease; ADP = Adenosine DiPhosphate; AA = Arachidonic Acid; AMI = Acute Myocardial Infarction; PFA = Platelet Function
Analyzer; EPI = Epinephrine; ACS = Acute Coronary Syndromes.
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cardiovascular disease whereas the remaining studies
included patients with acute coronary syndromes who un-
derwent primary percutaneous intervention. With regard to
the laboratory method used for identifying patients with
RPR, most of the included studies (n=8) used the PFA-100
system. As regarding statistical analysis, in addition, 6 out of11 studies reported statistical data not adjusted for potential
confounders.
3.3. Meta-analyses
The cumulative analysis for patients with RPR on ASA
therapy showed a significant increased risk of cardiovascular
Fig. 1. RR and 95% CI for recurrent cardiovascular events in patients with residual platelet reactivity on acetyl salicylic acid therapy. Studies are listed in
chronological order by year of publication. Reference for each article is presented as number in parentheses. Results are for available analyses of recurrent
cardiovascular events, and may differ from the results of the total study populations. Boxes represent the relative risk (RR), and lines represent the 95%
confidence interval (CI) for studies. The diamond represents the pooled RR, and its width represents its 95% CI.
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pb0.00001) (Fig. 1). However, a significant heterogeneity
across studies was reported (I2: 62.7%; p=0.003). The study
by Poulsen et al. [18] resulted to significantly influence the
heterogeneity of the analysis; after exclusion of this study the
association was confirmed (RR: 3.56, 95%CI 2.36–5.36;
pb0.0001) and no significant heterogeneity was reported (I2:
30.3%; p=0.17). The funnel plot of effect size against stan-
dard error was broadly symmetric, so consistent with the
conclusion that there was no publication bias. In addition, the
association remained statistically significant even after ex-
clusion of studies that reported only crude unadjusted data
(n=5) (RR: 3.19, 95%CI 1.97–5.19, pb0.00001) (I2: 0%;
test of homogeneity p=0.59).
3.4. Sensitivity analyses
To further examine the association between RPR and
occurrence of cardiovascular recurrences we performed sub-
group analyses, by selecting studies according to some
specific variables. Accordingly, an increased risk of clinical
recurrences was observed when studies were subgrouped
according to the duration of follow-up [≥1 year, studies
n=8; RR: 2.51 (95%CI 1.46–4.32), p=0.0009; b1 year,
studies n=3; RR: 7.25 (95%CI 3.12–16.81), pb0.00001],
ASA dosage [≤100 mg, studies n=3; RR: 5.69 (95%CI
2.81–11.54), pb0.00001; N100 mg, studies n=6; RR: 2.45
(95%CI 1.45–4.19), p=0.002], patients' characteristics
[acute coronary syndromes, studies n=8; RR: 3.17 (95%CI1.68–6.00), p=0.0001; stable CHD, studies n=3; RR: 3.02
(95%CI 1.26–7.26), pb0.0001], and method used for
determining RPR [PFA-100, studies n=8; RR: 2.52 (95%
CI 1.44–4.41), p=0.001; platelet aggregation, studies n=3;
RR: 5.82 (95%CI 2.99–11.34), pb0.0001].
4. Discussion
The present meta-analysis conducted in 11 prospective
studies, with an overall population of 1952 CHD patients
followed for a time ranging from 6 days to 4 years, showed a
significant increased risk of clinical recurrences for patients
who manifested RPR on ASA treatment. This association
remained statistically significant evenwhen subgroup analyses
according to the duration of follow-up, ASA dosage, patients'
characteristics, and laboratory method were performed.
ASA is currently the most effective therapeutic option for
secondary prevention of fatal and non fatal cardiovascular
events in patients with cardiovascular disease. Its clinical
effectiveness for patients suffering from various vascular
diseases has beenwell established inmany clinical trials and in
meta-analyses [1]. However, in a proportion of patients with
cardiovascular disease under ASA treatment, RPR, the so-
called aspirin resistance, is detectable [2]. Estimates of the
prevalence of RPR in clinical trials vary enormously, ranging
from 0% to over than 50% [4–6]. In a recent systematic review
of all the clinical trials that evaluated persistent platelet
reactivity in patients under ASA therapy, the mean prevalence
of RPR was nearly 25% [3]. Some clinical prospective studies
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currence of secondary cardiovascular events [4–6], and a
recent meta-analysis by Snoep et al. [7] reported a significant
role for the laboratory-defined aspirin resistance on the risk of
clinical cardiovascular recurrences.
In the present meta-analysis we confirm the data recently
published by Snoep et al. [7], by systematically analysing all
the published clinical studies that evaluated platelet function
among patients with CHD on ASA therapy. This in order to
give further insights on this matter that is arousing increasing
clinical interest among physicians and researchers. The main
result of our study is that CHD patients with a laboratory
evidence of RPR on ASA therapy were at an increased risk
of clinical recurrences. This datum, though not conclusive,
gives strong stimulus to researchers to continue working in
this field.
To date, the mechanism of RPR on ASA therapy is still
uncertain. Some investigators reported a nonadherence to
therapy as the main cause of persistent platelet activation, by
hypothesising this phenomenon only as “non-compliance”
[19]. Others, instead, hypothesised that the interaction of
platelets with other cells, as well as the presence of poly-
morphisms in genes encoding for proteins involved in the
platelet function may help to explain the pathophysiological
basis for RPR in these patients [20–24]. Additionally, diabetes,
duration of ASA therapy and dosage have been also
demonstrated to likely contribute in determining RPR [25].
Our meta-analysis suffers from some limitations that
strictly derive from the studies included in the final analysis.
Actually, a number of laboratory methods for the measure-
ment of RPR have been used, and there is not an accepted
uniform measure for screening platelet function in the
clinical setting. Furthermore, the studies differ substantially
for several features such as clinical setting of patients en-
rolled, ASA dosage, duration of treatment, laboratory
method, and definition of RPR, so determining a statistically
significance for the heterogeneity test of the cumulative
analysis. However, after exclusion of the study by Poulsen
et al. [18], which was not designed to investigate the
prognostic role of residual platelet reactivity on the occur-
rence of atherothrombotic events, the heterogeneity test lost
its significance. Finally, adherence to ASA therapy has not
been systematically assessed, and most of the included
studies lack of adjustment for confounding factors in the
multivariable statistical models. However, subgroup ana-
lyses conducted according to some specific variables, i.e.
laboratory method, duration of ASA treatment and ASA
dosage confirmed the significant association observed be-
tween such phenomenon and the occurrence of secondary
clinical events, so being in line with the results of our
previous study documenting a concordance between differ-
ent methods used for the measurement of RPR on ASA [26].
In conclusion, the present meta-analysis conducted in 11
prospective studies and including over than 1900 patients
with CHD demonstrated that RPR is significantly associated
with an increased risk of recurrent cardiovascular events, bypossibly suggesting a clinical implication of RPR, though in
apparent contrast with the indications of the scientific as-
sociations [27]. However, more prospective studies are
needed to determine the independent prognostic importance
of RPR during aspirin therapy and the possible benefit of
individually tailored anti-platelet treatment strategies in these
patients.
References
[1] Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis
of randomised trials of antiplatelet therapy for prevention of death,
myocardial infarction, and stroke in high risk patients. BMJ
2002;324:71–86.
[2] Gum PA, Kottke-Marchant K, Poggio ED, et al. Profile and prevalence
of aspirin resistance in patients with cardiovascular disease. Am
J Cardiol 2001;88:230–5.
[3] Hovens MMC, Snoep JD, Eikelboom JCJ, van der Bom JG, Mertens
BJA, Huisman MV. Prevalence of persistent platelet reactivity despite
use of aspirin: a systematic review. Am Heart J 2007;153:175–81.
[4] Grotemeyer KH, Scharafinski HW, Husstedt IW. Two-year follow-up
of aspirin responder and aspirin non responder. A pilot-study including
180 post-stroke patients. Thromb Res 1993;71:397–403.
[5] HelgasonCM,BolinKM,Hoff JA, et al. Development of aspirin resistance
in persons with previous ischemic stroke. Stroke 1994;25:2331–6.
[6] Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-
resistant thromboxane biosynthesis and the risk of myocardial
infarction, stroke, or cardiovascular death in patients at high risk for
cardiovascular events. Circulation 2002;105:1650–5.
[7] Snoep JD, Hovens MMC, Eikenboom JCJ, van der Bom JG, Huisman
MV. Association of laboratory-defined aspirin resistance with a higher
risk of recurrent cardiovascular events. A systematic review and meta-
analysis. Arch Intern Med 2007;167:1593–9.
[8] Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A
prospective, blinded determination of the natural history of aspirin
resistance among stable patients with cardiovascular disease. J Am
Coll Cardiol 2003;41:961–5.
[9] Andersen K, Hurlen M, Amesen H, Seljeflot I. Aspirin non-
responsiveness as measured by PFA-100 in patients with coronary
artery disease. Thromb Res 2003;108:37–42.
[10] Marcucci R, Paniccia R, Antonucci E, et al. Usefulness of aspirin
resistance after percutaneous coronary intervention for acute myocar-
dial infarction in predicting one-year major adverse coronary events.
Am J Cardiol 2006;98:1156–9.
[11] Gianetti J, Parri MS, Sbrana S, et al. Platelet activation predicts
recurrent ischemic events after percutaneous coronary angioplasty: a
6 months prospective study. Thromb Res 2006;118:487–93.
[12] Fuchs I, Frossard M, Spiel A, Riedmuller E, Laggner AN, Jilma B.
Platelet function in patients with acute coronary syndrome (ACS)
predicts recurrent ACS. J Thromb Haemost 2006;4:2547–52.
[13] Stejskal D, Vaclavik J, Lacnak B, Proskova J. Aspirin resistance
measured by cationic propyl gallate platelet aggregometry and
recurrent cardiovascular events during 4 years of follow-up. Eur
J Intern Med 2006;17:349–54.
[14] Pamukcu B, Oflaz H, Oncul A, et al. The role of aspirin resistance on
outcome in patients with acute coronary syndrome and the effect of
clopidogrel therapy in the prevention of major cardiovascular events.
J Thromb Thrombolysis 2006;22:103–10.
[15] Cuisset T, Frere C, Quilici J, et al. High post-treatment platelet
reactivity identified low-responders to dual antiplatelet therapy at
increased risk of recurrent cardiovascular events after stenting for acute
coronary syndrome. J Thromb Haemost 2006;4:542–9.
[16] Malek LA, Spiewak M, Filipiak KJ, et al. Persistent platelet activation
is related to very early cardiovascular events in patients with acute
coronary syndromes. Kardiol Pol 2007;65:40–5.
171F. Sofi et al. / International Journal of Cardiology 128 (2008) 166–171[17] PamukcuB,OflazH, Onur I, et al. Clinical relevance of aspirin resistance
in patients with stable coronary artery disease: a prospective follow-up
study (PROSPECTAR). Blood Coagul Fibrinolysis 2007;18:187–92.
[18] Poulsen TS, Kristensen RS, Korsholm L, et al. Variation and
importance of aspirin resistance in patients with cardiovascular
disease. Thromb Res 2007;120:477–84.
[19] Cotter G, Shemesh E, Zehavi M, et al. Lack of aspirin effect: aspirin
resistance or resistance to taking aspirin? AmHeart J 2004;147:293–300.
[20] Valles J, Santos MT, Aznar J, et al. Erythrocyte promotion of platelet
reactivity decreases the effectiveness of aspirin as an antithrombotic
therapeutic modality: the effect of low-dose aspirin is less than optimal
in patients with vascular disease due to prothrombotic effects of
erythrocytes on platelet reactivity. Circulation 1998;97:350–5.
[21] Michelson AD, Furman MI, Goldschmidt-Clermont P, et al. Platelet
GP IIIa Pl(A) polymorphisms display different sensitivities to agonists.
Circulation 2000;101:1013–8.
[22] Cipollone F, Rocca B, Patrono C. Ciclooxygenase-2 expression and
inhibition in atherothrombosis. Arterioscler Thromb Vasc Biol
2004;24:246–55.[23] Giusti B, Gori AM, Marcucci R, et al. Role of glycoprotein Ia gene
polymorphisms in determining platelet function in myocardial
infarction patients undergoing percutaneous coronary intervention on
dual antiplatelet treatment. Atherosclerosis 2006 doi:10.16/j.
atherosclerosis.2006.11.009.
[24] Mannini L, Marcucci R, Paniccia R, et al. Erythrocyte deformability
andwhite blood cell count are associatedwith aspirin resistance in high-
risk vascular patients. Clin Hemorheol Microcirc 2006;35:175–81.
[25] Pulcinelli FM, Pignatelli P, Celestini A, Riondino S, Gazzaniga PP, Violi
F. Inhibition of platelet aggregation by aspirin progressively decreases in
long-term treated patients. J Am Coll Cardiol 2004;43:979–84.
[26] Paniccia R, Antonucci E, Gori AM, et al. Comparison of different
methods to evaluate the effect of aspirin on platelet function in high
risk patients with ischemic heart disease on dual antiplatelet treatment.
Am J Clin Pathol 2007;128:143–9.
[27] Michelson AD, Cattaneo M, Eikelboom JW, et al. Aspirin resistance:
position paper of the Working Group on Aspirin Resistance. J Thromb
Haemost 2005;3:1309–11.
